Modelling the past, current and future HCV burden in France: Detailed analysis and perspectives

Statistical Methods in Medical Research

Volumn 18, Issue 3, 2009, Pages 233-252

  Deuffic Burban, Sylvie ^a,b   Mathurin, Philippe ^a   Valleron, Alain Jacques ^c  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ CATHOLIQUE DE LILLE   (France)

^c HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER MORTALITY; CONTROLLED STUDY; DEATH; DISEASE COURSE; EPIDEMIC; EPIDEMIOLOGICAL DATA; FEMALE; FRANCE; HEALTH CARE AVAILABILITY; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL ANALYSIS; MORTALITY; PREDICTION; PROBABILITY; PUBLIC HEALTH SERVICE; STATISTICAL ANALYSIS; STATISTICAL MODEL;

EID: 66649090648     PISSN: 09622802     EISSN: None     Source Type: Journal    
DOI: 10.1177/0962280208094697     Document Type: Article

References (60)

1. Meffre C., Le Strat Y., Delarocque-Astagneau E., Meyer J., Coste D., Steinmetz J. Prevalence of hepatitis C in France, 2003-2004. 41st annual meeting of the European association for the study of the liver, 2006, April 26-30; Vienna, Austria, 2006.
2. Deuffic S., Buffat L., Poynard T., Valleron AJ Modeling the hepatitis C virus epidemic in France. Hepatology 1999; 29: 1596-601.
3. Deuffic-Burban S., Wong JB, Valleron A-J., Costagliola D., Delfraissy JF, Poynard T. Comparing the public health burden of chronic hepatitis C and HIV infection in France. J Hepatol 2004; 40: 319-26.
4. Hutchinson SJ, Bird SM, Goldberg DJ Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland. Hepatology 2005; 42: 711-23.
5. Law MG, Dore GJ, Bath N., Thompson S., Crofts N., Dolan K. et al. Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. Int J Epidemiol 2003; 32: 717-24.
6. Razali K., Thein HH, Bell J., Cooper-Stanbury M., Dolan K., Dore G. et al. Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend 2007; 91: 228-35.
7. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31: 777-82.
8. Wong J., McQuillan GM, McHutchinson JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90: 1562-9.
9. Sypsa V., Touloumi G., Papatheodoridis GV, Tassopoulos NC, Ketikoglou I., Vafiadis I. et al. Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments. J Viral Hepat 2005; 12: 543-50.
10. Sypsa V., Touloumi G., Tassopoulos NC, Ketikoglou I., Vafiadis I., Hatzis G. et al. Reconstructing and predicting the hepatitis C virus epidemic in Greece: Increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection. J Viral Hepat 2004; 11: 366-74.
11. Law MG Modelling the hepatitis C virus epidemic in Australia. Journal of Gastroenterology and Hepatology 1999; 14: 1100-7.
12. Brookmeyer R. Reconstruction and future trends of the AIDS epidemic in the United States. Science 1991; 253: 37-42.
13. Brookmeyer R., Gail M. The minimum size of the AIDS epidemic in the United States. Lancet 1986; ii: 1320-2.
14. Poynard T., Bedossa P., Opolon P., for the OBSVIRC, METAVIR, CLINIVIR, DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-32.
15. Alter MJ, Margolis HS, Krawczynski K., Judson FN, Mares A., Alexander WJ et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992; 327: 1899-905.
16. Koretz RL, Brezina M., Polito AJ, Quan S., Wilber J., Dinello R. et al. Non-A, non-B posttransfusion hepatitis: Comparing C and non-C hepatitis. Hepatology 1993; 17: 361-5.
17. Tremolada F., Casarin C., Tagger A., Ribero ML, Realdi G., Alberti A. et al. Antibody to hepatitis C virus in post-transfusion hepatitis. Ann Intern Med 1991; 114: 277-81.
18. Tremolada F., Casarin C., Alberti A., Drago C., Tagger A., Ribero ML et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 1992; 16: 273-81.
19. Fattovich G., Giustina G., Degos F., Tremolada F., Diodati G., Almasio P. et al. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-72.
20. Takano S., Yokosuka O., Imazeki F., Tagawa M., Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: A prospective study of 251 patients. Hepatology 1995; 21: 650-5.
21. Benvegnu L., Fattovich G., Noventa F., Tremolada F., Chemello L., Cecchetto A. et al. Concurrent Hepatitis B and C Virus infection and risk of hepatocellular carcinoma in cirrhosis. Cancer 1994; 74: 2442-8.
22. Mandelli C., Fraquelli M., Fargion S., Barisani D., Piperno A., Braga M. et al. Comparable frequency of hepatocellular carcinoma in cirrhosis of different aetiology. European Journal of Gastroenterology & Hepatology 1994; 6: 1129-34.
23. Serfaty L., Aumaitre H., Chazouilleres O., Bonnand AM, Rosmorduc O., Poupon RE et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998; 27: 1435-40.
24. Ikeda K., Saitoh S., Koida I., Arase Y., Tsubota A., Chayama K. et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993; 18: 47-53.
25. Tsai JF, Jeng JE, Ho MS, Chang WY, Hsieh MY, Lin ZY et al. Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: A prospective study. Br J Cancer 1997; 76: 968-74.
26. Ng IO, Lai EC, Fan ST, Ng MM, So MK Prognostic significance of pathologic features of hepatocellular carcinoma. A multivariate analysis of 278 patients. Cancer 1995; 76: 2443-8.
27. The Liver Cancer Study Group of Japan. Primary liver cancer in Japan. Ann Surg 1990; 211: 277-87.
28. Ducreux M., Buffet C., Dussaix E., Pelletier G., Briantais MJ, Yvart J. et al. Antibodies to hepatitis C virus in hepatocellular carcinoma [letter]. Lancet 1990; 335: 301.
29. Nalpas B., Driss F., Pol S., Hamelin B., Housset C., Bréchot C. et al. Association between HCV and HBV infection in hepatocellular carcinoma and alcoholic liver disease. J Hepatol 1991; 12: 70-4.
30. Zarski JP, Lunel F., Dardelet D., Thelu MA, Baccard M., Perrin M. et al. Hepatitis C virus and hepatocellular carcinoma in France: Detection of antibodies using two second generation assays. J Hepatol 1991; 13: 376-7.
31. Dubois F., Desenclos JC, Mariotte N., Goudeau A., the Collaborative Study Group. Hepatitis C in a French population-based survey, 1994: Seroprevalence, frequency of viremia, genotype distribution, and risk factors. Hepatology 1997; 25: 1490-6.
32. Fong KW, Jefferson TH, Suyehiro T., Walton L. SLATEC Common Mathematical Library. 1993.
33. Marquardt D. An algorithm for least-squares estimation of nonlinear parameters. J Soc Indust Appl Math 1963; 11: 431-41.
34. Press WH, Flannery BP, Teukolsky SA, Vetterling WT Numerical recipes in C. Cambridge: Cambridge University Press; 1988.
35. Bennett WG, Inoue Y., Beck JR, Wong JB, Pauker SG, Davis GL Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127: 855-65.
36. Kim WR, Poterucha JJ, Hermans JE, Therneau TM, Dickson ER, Evans RW et al. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med 1997; 127: 866-74.
37. Delladetsima JK, Rassidakis G., Tassopoulos NC, Papatheodoridis GV, Smyrnoff T., Vafiadis I. Histopathology of chronic hepatitis C in relation to epidemiological factors. J Hepatol 1996; 24: 27-32.
38. Kage M., Shimamatu K., Nakashima E., Kojiro M., Inoue O., Yano M. Long-term evolution of fibrosis from chronic hepatitis to cirrhosis in patients with hepatitis C: Morphometric analysis of repeated biopsies. Hepatology 1997; 25: 1028-31.
39. Lucidarme D., Dumas F., Arpurt JP, Pariente EA, Naudin G., Forzy G. et al. Age at the time of hepatitis C contamination might be an important predictive factor of progression to cirrhosis. Presse Med 1998; 27: 608-11.
40. Ostapowicz G., Watson KJR, Locarnini SA, Desmond PV Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology 1998; 27: 1730-5.
41. Pessione F., Degos F., Marcellin P., Duchatelle V., Njapoum C., MartinotPeignoux M. et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998; 27: 1717-22.
42. Pol S., Fontaine H., Carnot F., Zylberberg H., Berthelot P., Bréchot C. et al. Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C: A comparison between immunocompetent and immunocompromised patients. J Hepatol 1998; 29: 12-9.
43. Poynard T., Bedossa P., BioulacSage P., Callard P., Chevallier M., Degott C. et al. Age and platelet count: A simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. J Viral Hepatitis 1997; 4: 199-208.
44. Roudot-Thoraval F., Bastie A., Pawlotsky JM, Dhumeaux D., Audigier JC, Barbare JC et al. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: A French Survey of 6,664 patients. Hepatology 1997; 26: 485-90.
45. Simmonds P., Mellor J., Craxi A., Sanchez-tapias JM, Alberti A., Prieto J. et al. Epidemiological, clinical and therapeutic associations of hepatitis C types in western European patients. J Hepatol 1996; 24: 517-24.
46. Tassopoulos NC, Papatheodoridis GV, Katsoulidou A., Delladetsima JK, Sypsa V., Touloumi G. et al. Factors associated with severity and disease progression in chronic hepatitis C. Hepatogastroenterology 1998; 45: 1678-83.
47. Vaquer P., Canet R., Llompart A., Riera J., Obrador A., Gaya J. Histological evolution of chronic hepatitis C. Factors related to progression. Liver 1994; 14: 265-9.
48. Verbaan H., Hoffmann G., Lindgren S., Nilsson S., Widell A., Eriksson S. Long-term outcome of chronic hepatitis C infection in a low-prevalence area. Scand J Gastroenterol 1998; 33: 650-5.
49. Wong V., Caronia S., Wight D., Palmer CR, Petrik J., Britton P. et al. Importance of age in chronic hepatitis C virus infection. J Viral Hepatitis 1997; 4: 255-64.
50. Bird SM, Goldberg DJ, Hutchinson SJ Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Part 2: Preliminary UK estimates of prevalent injection-related hepatitis C carriers, and derivation of progression rates to liver cirrhosis by gender and age at hepatitis C virus infection. J Epidemiol Biostat 2001; 6: 267-77; discussion 79-85.
51. Degos F., Christidis C., Ganne-Carrié N., Farmachidi J-P., Degott C., Guettier C. et al. Hepatitis C virus related cirrhosis: Time to occurrence of hepatocellular carcinoma and death. Gut 2000; 47: 131-6.
52. El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 2001; 33: 62-5.
53. Pagliaro L., Peri V., Linea C., Camma C., Giunta M., Magrin S. Natural history of chronic hepatitis C. Italian J Gastroenterol Hepatol 1999; 31: 28-44.
54. Agence Nationale d'Accréditation et d'Evaluation en Santé. Traitement de l'hépatite C (French). Conférence de consensus; 2002, 27-28 February, Paris, 2002.
55. Manns M., McHutchinson JG, Gordon S., Rustgi V., Shiffman ML, Reindollar R. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958-65.
56. Bréchot C., Jaffredo F., Lagorce D., Gerken G., zumBuschenfelde KM, Papakonstontinou A. et al. Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: Results of a European concerted action. J Hepatol 1998; 29: 173-83.
57. Freeman AJ, Dore GJ, Law MG, Thorpe M., Von Overbeck J., Lloyd AR et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 809-16.
58. Marcellin P., Pequignot F., Delarocque-Astagneau E., Zarski JP, Ganne N., Hillon P. et al. Mortality related to chronic hepatitis B and chronic hepatitis C in France: Evidence for the role of HIV coinfection and alcohol consumption. J Hepatol 2008; 48: 200-7.
59. McDonald SA, Donaghy M., Goldberg DJ, Hutchinson SJ, Robestson C., Bird SM, Mills PR, Dillon J., Bloor M., Hayes P., Graham L. A population-based record linkage study of mortality in hepatitis C-diagnosed persons with or without HIV coinfection in Scotland. Statistical Methods in Medical Research 2008; DOI: 10.1177/ 0962280208094890
60. Deuffic-Burban S., Deltenre P., Louvet A., Canva V., Dharancy S., Hollebecque A., Boitard J., Henrion J., Yazdanpanah Y., Mathurin P. Impact of viral eradication on mortality related to hepatitis C: A modeling approach in France. J Hepatol 2008; 49: 175-83.